Phase 1/2Completed
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)
A Phase 1/2a, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravenous Administration of RGI-2001 in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)
- Sponsor
- Regimmune Corporation (Industry)
- Enrollment
- 68 enrolled
- Conditions
- Graft Versus Host Disease
- Interventions
- RGI-2001; Calcineurin Inhibitors; Allogeneic Hematopoietic Stem Cell Transplantation; Conditioning Regimen; Allogeneic Bone Marrow Transplantation; Methotrexate; Mofetil Mycophenolate; sirolimus
- Ages
- adults, older adults
- Registry
- NCT01379209
Full record on ClinicalTrials.gov
From the registry
The clinical trial is a Phase 1/2a, open-label, multi-center, dose-escalation study to evaluate the safety, tolerability and pharmacokinetic profile of RGI-2001 in patients undergoing AHSCT, with radiation or non-radiation myeloablative preparative treatment. The study will be separated into two parts; a dose escalation phase to assess safety, followed by a large expansion phase to further evaluate the pharmacologic effects of either a Maximum Tolerated Dose, Maximum Feasible Dose or optimal pharmacologically active dose of RGI-2001. The initial dose escalation safety portion of the study (Part 1) will include higher risk patients and limit the unrelated donor transplants. After safety is established in part 1 of the study, the second portion of the study will expand the enrollment criteria and allow transplantation by either related or unrelated donors. This study will endeavor to identify the dose range at which RGI-2001 has an acceptable safety profile, at which biologic activity is observed, and to guide possible dose levels to utilize in later phase studies based on…
Primary outcomes
- The maximum tolerated dose (MTD) or maximum feasible dose (MFD) of RGI-2001
History
Last registry update
Study completion
Primary completion
Started
Registered